Novel CD9-targeted therapies in gastric cancer
Authors:
Open Access
- 21 March 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (11) , 3206-3213
Abstract
There are 33 human tetraspanin proteins, emerging as key players in malignancy, the immune system, fertilization, cellular signaling, adhesion, morphology, motility, proliferation, and tumor invasion. CD9, a member of the tetraspanin family, associates with and influences a variety of cell-surface molecules. Through these interactions, CD9 modifies multiple cellular events, including adhesion, migration, proliferation, and survival. CD9 is therefore considered to play a role in several stages during cancer development. Reduced CD9 expression is generally related to venous vessel invasion and metastasis as well as poor prognosis. We found that treatment of mice bearing human gastric cancer cells with anti-CD9 antibody successfully inhibited tumor progression via antiproliferative, proapoptotic, and antiangiogenic effects, strongly indicating that CD9 is a possible therapeutic target in patients with gastric cancer. Here, we describe the possibility of CD9 manipulation as a novel therapeutic strategy in gastric cancer, which still shows poor prognosis.Keywords
This publication has 76 references indexed in Scilit:
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinomaWorld Journal of Surgical Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Adenoviral Transduction ofMRP-1/CD9andKAI1/CD82Inhibits Lymph Node Metastasis in Orthotopic Lung Cancer ModelCancer Research, 2007
- MRP-1/CD9 gene transduction downregulates Wnt signal pathwaysOncogene, 2004
- CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cellsJournal of Cell Science, 2004
- EWI-2 regulates α3β1 integrin–dependent cell functions on laminin-5Journal of Cell Biology, 2003
- Significance of the association between heparin‐binding epidermal growth factor‐like growth factor and CD9 in human gastric cancerInternational Journal of Cancer, 2002
- Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinomaBritish Journal of Cancer, 1999